Mestinon (Pyridostigmine Bromide)

Pyridostigmine is a reversible acetylcholinesterase inhibitor. By binding to the enzyme that breaks down acetylcholine, it slows the degradation of this neurotransmitter, allowing higher concentrations to persist at nicotinic receptors. The result is enhanced muscle contraction and improved gastrointestinal motility.

The appropriate dose of Mestinon is individualized by the prescribing clinician based on the patient’s condition, severity, renal function, and response to therapy. Dosage adjustments are made during treatment to achieve optimal clinical benefit while minimizing side effects.

Safety data for pyridostigmine bromide in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant.

To request Mestinon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mestinon and neostigmine belong to the same drug class but differ in pharmacokinetics. Pyridoxidine bromide has a longer duration of action and is taken orally, whereas neostigmine is shorter‑acting and often administered intravenously or intramuscularly. The oral route of Mestinon offers convenient chronic management for myasthenia gravis.

Mestinon tablets should be stored at temperatures below 25 °C, in their original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity, which could affect potency.

Mestinon is supplied as oral tablets that are swallowed whole with a glass of water. It is usually taken several times a day, with dosing times spaced evenly. Patients should follow the prescribing clinician’s instructions regarding food intake, as meals may influence absorption.

The most critical adverse events include cholinergic crisis, which can cause severe muscle weakness and respiratory failure, and profound bradycardia that may lead to syncope. Anaphylactic reactions, though rare, require immediate medical attention. Promptly report any signs of excessive sweating, muscle twitching, or difficulty breathing.

Mestinon is contraindicated in individuals with known hypersensitivity to pyridostigmine or any excipients, in patients with mechanical intestinal obstruction, and in those with severe asthma or chronic obstructive pulmonary disease where cholinergic stimulation could worsen bronchospasm. Caution is also advised for patients with significant renal impairment.